% | $
Quotes you view appear here for quick access.

Neuralstem, Inc. Message Board

  • indianabraden indianabraden Jan 6, 2013 5:23 PM Flag

    Seeking Alpha ( BioWire) - Positive PP referencing CUR and data in ALS


    " With regards to Athersys in particular, it's not too surprising that the stock actually went down following the aforementioned press release. Not only has the market caught onto the idea that preclinical results for stem cells are overrated, but it's also worth noting that other stem cell companies have already established more competitive profiles in neuron regeneration. Consider Neuralstem (NASDAQ: CUR), with their NSI-566 line. This company has already demonstrated some tangible results in the treatment of amyotrophic lateral sclerosis (ALS), which is more commonly known as Lou Gherig's disease, in a phase I trial. "

    Sentiment: Strong Buy

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.343-0.017(-4.72%)May 27 4:00 PMEDT